Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.
Milas
L
L
L. Milas, K. Kishi, N. Hunter, K. Mason, P. J. Tofilon, Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston.
Kishi
K
K
Hunter
N
N
Mason
K
K
Masferrer
J L
JL
Tofilon
P J
PJ
D000818:Animals; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D005720:Gamma Rays; D007527:Isoenzymes / Q000187:drug effects*; D051379:Mice; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*; D011720:Pyrazoles / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D012513:Sarcoma, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D013449:Sulfonamides / Q000494:pharmacology*; D000096926:Benzenesulfonamides
D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D011838:Radiation-Sensitizing Agents; D013449:Sulfonamides; C119130:4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; D000096926:Benzenesulfonamides